Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3,220.99 – $5,065.37
42% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.53B | $6.20B | $6.32B | $6.68B | $7.12B | $6.92B | $7.41B | $7.47B |
| Cost of revenue | $3.20B | $3.67B | $3.66B | $3.83B | $4.36B | $4.07B | $4.14B | $4.22B |
| Gross profit | $2.33B | $2.53B | $2.66B | $2.85B | $2.76B | $2.85B | $3.27B | $3.25B |
| Gross margin | 42.1% | 40.8% | 42.1% | 42.7% | 38.8% | 41.2% | 44.1% | 43.5% |
| R&D | $477.0M | $528.0M | $536.0M | $562.0M | $522.0M | $519.0M | $565.0M | $551.0M |
| Operating income | $883.0M | $920.0M | $996.0M | $1.09B | $1.11B | $1.12B | $1.39B | $1.38B |
| EBITDA | $1.11B | $1.24B | $1.35B | $1.45B | $1.39B | $1.47B | $1.79B | $1.79B |
| Net income | $663.0M | $702.0M | $743.0M | $821.0M | $856.0M | $893.0M | $1.09B | $1.07B |
| Net margin | 12.0% | 11.3% | 11.8% | 12.3% | 12.0% | 12.9% | 14.7% | 14.3% |
| EPS (diluted) | 71.36 | 75.59 | 79.96 | 88.37 | 92.51 | 96.47 | 117.63 | 115.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7.4B | $118.48 | $115.72–$123.04 | 7 |
| 2027 | $7.9B | $128.72 | $125.72–$133.67 | 3 |
| 2028 | $8.2B | $136.57 | $133.40–$141.83 | 4 |
| 2029 | $8.5B | $142.94 | $139.61–$148.44 | 3 |
Forward consensus · source: Financial Modeling Prep
GIVAUDAN AG
No one on the platform currently holds GVDBF.
No tracked institution reports a position in GVDBF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-24 | $72.0000 | 2026-03-25 |
| 2025-03-25 | $70.0000 | 2025-03-26 |
| 2024-03-25 | $68.0000 | 2024-03-27 |
No one on the platform has traded GVDBF yet.
| $33.3B |
| — |
| NVZMFNovozymes A/S | $60.60 | -0.08% | $28.3B | — |
| NVZMYNovozymes A/S | $63.24 | +1.39% | $29.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$GVDBF $SYIEF $IFF Cohen Milstein Investigates Givaudan, Symrise, International Flavors & Fragrances, Firmenich for Alleged Price-Fixing Antitrust Violations https://www.stocktitan.net/news/GVDBF/cohen-milstein-investigates-givaudan-symrise-international-flavors-lu5ldw7u9ejx.html
View on StockTwits ↗$GVDBF - About 17.0% of the company shares are held by… https://www.macroaxis.com/stock-analysis/GVDBF/Givaudan-SA #insidertrading #stocks #fintechnews
View on StockTwits ↗$GVDBF Does anyone know the ownership in the company of various members of the board at Givaudan (more specfically, does anyone own a significant amount?)
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 21.1× earnings vs its 37.7× historical median P/E.
Fair value ≈ $7118 · price $3991 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.